Drug Trial Radar · NCT07704697
Assess Sacubitril/Allisartan and Amlodipine in Patients With Essential Hypertension Uncontrolled With Sacubitril/Allisartan
Last checked: Nov 20, 2026Latest source record: Jul 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
346
Actual
Start
Nov 23, 2024
Primary completion
Nov 10, 2025
Study completion Nov 24, 2025
Sponsor
- Lead sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 15, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main objective of the study will be to assess the efficacy and safety of Sacubitril/Allisartan (240mg) and Amlodipine (5mg) in patients with essential hypertension uncontrolled after 4-week treatment with Sacubitril/Allisartan (240mg).
Conditions
- Essential Hypertension
Interventions
Experimental: Sacubitril/Allisartan and Amlodipine GroupDrug
Drug: Sacubitril/Allisartan and Amlodipine
Active Comparator: Sacubitril/Allisartan GroupDrug
Drug: Sacubitril/Allisartan
Primary outcomes
What the sponsor says the trial is designed to measure.
- The baseline change in mean seated systolic blood pressure (msSBP)Time frame: at 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University First Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.